Boyapati A, et al. High Baseline Serum IL-6 Identifies a Subgroup of Rheumatoid Arthritis Patients with Rapid Joint Damage and Clinical Progression and Predicts Increased Sarilumab Treatment Response. ACR 2018, abstract L08.
Amsterdam UMC en Reade werken samen aan betere zorg voor patiënten met spondyloartritis
jul 2025 | Spondyloartritis